Global menu

Our global pages

Close

Eversheds Sutherland advises Otsuka Novel Products GmbH on strategic global collaboration

  • Germany
  • Global
  • United Kingdom

    02-04-2020

    Eversheds Sutherland has advised Otsuka Novel Products GmbH on a strategic global collaboration to develop transformative treatment regimens for tuberculosis with the Bill & Melinda Gates Medical Research Institute and the Bill & Melinda Gates Foundation and Evotec, GSK, Johnson & Johnson and Otsuka Pharmaceutical Co., Ltd., based in Japan.

    Eversheds Sutherland provided advice on all aspects of the matter, from the early stage of setting up a term sheet between the different members, to all the negotiations on complex regulatory and intellectual property law issues on a global scale, addressing the different needs and demands of philanthropic, non-profit and private sector organizations.

    Tobias Maier, co-head of the health and life sciences sector and a Partner in Eversheds Sutherland’s IP and Commercial practice led the team, with support from Nils Müller, Principal Associate, and Magdalena Kotyrba, Senior Associate (all Munich).

    Tobias Maier commented:

    “We are delighted to have helped Otsuka Novel Products GmbH to be part of  a ground-breaking collaboration with the other collaborators to accelerate the development of novel TB treatment regimens.”

    The complete project was driven by the senior management and senior legal in-house teams of the respective parties, see here.

    Disclaimer

    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back

    Print Friendly and PDF
    Register to receive regular updates via email.